How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Human Primary Cells Market
- By Cell Type: Epithelial Cells, Endothelial Cells, Fibroblasts, Hematopoietic Stem Cells, Neuronal Cells, Mesenchymal Stem Cells
- By Source Tissue: Bone Marrow, Adipose Tissue, Umbilical Cord, Peripheral Blood, Skin, Liver
- By Application: Drug Discovery and Development, Toxicology Testing, Regenerative Medicine, Cancer Research, Stem Cell Research
- By Product Type: Cryopreserved Primary Cells, Fresh Primary Cells, Cultured Primary Cells, Cell Banks
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Epithelial Cells leads By Cell Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 306 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Human Primary Cells Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Cell Type 6
Source Tissue 6
Application 5
Product Type 4
End User 4
Companies profiled
Thermo Fisher Scientific
Lonza Group
Merck KGaA (MilliporeSigma)
PromoCell GmbH
ATCC (American Type Culture Collection)
BioIVT
Cell Applications Inc.
Zen-Bio Inc.
ScienCell Research Laboratories
Crown Bioscience
Creative Bioarray
Sartorius AG
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PromoCell GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ATCC (American Type Culture Collection)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →BioIVT
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cell Applications Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zen-Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →ScienCell Research Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Crown Bioscience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Creative Bioarray
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sartorius AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →STEMCELL Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cell Biologics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Innoprot
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$567.9M by 2033 · 3.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Epithelial Cells46.1
- Endothelial Cells13.6
- Fibroblasts15.2
- Hematopoietic Stem Cells7.0
- Neuronal Cells7.5
- Mesenchymal Stem Cells10.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$141.6M → $174.3M · 2.6%
Europe$98.7M → $139.5M · 4.4%
Asia Pacific$90.1M → $133.3M · 5.0%
Latin America$55.8M → $81.4M · 4.8%
Middle East and Africa$42.9M → $57.0M · 3.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.512026
3.542027
3.532028
3.552029
3.572030
3.572031
3.582032
3.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific18.4
- Lonza Group17.4
- Merck KGaA (MilliporeSigma)5.8
- PromoCell GmbH4.9
- ATCC (American Type Culture Collection)12.5
- BioIVT12.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Cell Type10.4%
Source Tissue17.5%
Application19.4%
Product Type20.1%
End User32.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.8
- Europe23.8
- Asia Pacific22.8
- Latin America13.9
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 83 | 92 | 82 | 76 | 85 | 93 | 85 |
| Lonza Group | 77 | 80 | 79 | 83 | 74 | 85 | 80 |
| Merck KGaA (MilliporeSigma) | 83 | 70 | 80 | 63 | 67 | 73 | 73 |
| PromoCell GmbH | 70 | 75 | 75 | 78 | 70 | 77 | 74 |
| ATCC (American Type Culture Collection) | 75 | 56 | 58 | 71 | 52 | 52 | 61 |
| BioIVT | 62 | 53 | 58 | 55 | 68 | 53 | 58 |
| Cell Applications Inc. | 60 | 63 | 63 | 63 | 47 | 51 | 58 |
| Zen-Bio Inc. | 49 | 60 | 41 | 55 | 49 | 60 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Lonza Group
- Merck KGaA (MilliporeSigma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Lonza Group | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Merck KGaA (MilliporeSigma) | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| PromoCell GmbH | − | ✓ | ✓ | ◐ | ◐ | ✓ |
| ATCC (American Type Culture Collection) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| BioIVT | − | − | − | − | ◐ | − |
| Cell Applications Inc. | − | ◐ | ◐ | ◐ | − | ◐ |
| Zen-Bio Inc. | − | ◐ | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific85
2Lonza Group80
3PromoCell GmbH74
4Merck KGaA (MilliporeSigma)73
5ATCC (American Type Culture Collection)61
6BioIVT58
7Cell Applications Inc.58
8Zen-Bio Inc.52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificLonza Group
Challenger2
Strong scale, closing on the leaders.
Merck KGaA (MilliporeSigma)PromoCell GmbH
Contender3
Focused players with pockets of strength.
ATCC (American Type Culture Collection)BioIVTCell Applications Inc.
Niche1
Specialists in a single segment or region.
Zen-Bio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Cell Type in North America, then scale across Human Primary Cells Market — a $69M beachhead inside a $1.30B market.
Beachhead (SOM)$69Mobtainable near-term
Serviceable (SAM)$463Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Epithelial Cells
Best fit — highest urgency & budget in Cell Type.
Economic buyer75 fit
Endothelial Cells
Strong fit — clear ROI and a fast path to value.
End user65 fit
Fibroblasts
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Cell Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Source Tissue & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Cell Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Human Primary Cells Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified23%
Evaluation14%
Closed-won8%
$15.2KCAC
$83KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Human Primary Cells Market is a resilient opportunity — $4.68B by 2033, compounding at 4.8%.
TAM · 2025$3.23Btoday
TAM · 2033$4.68Bforecast
CAGR4.8%2027–2033
Cumulative$35.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.68BTotal addressable market
SAM$1.86BServiceable available market
SOM$302MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Cell Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Cell Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.68BLarge & growingTAM by 2033 at 4.8% CAGR
$1.86BServiceable nowreachable with today’s model
$302MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.65BBear3.1% CAGR
$4.68BBase4.8% CAGR
$5.99BBull6.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Source Tissue optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Human Primary Cells Market — a $8.01B market by 2033. Plan: grow share from 9.3% to 15.7%.
Market size · 2033$8.01Btotal addressable
Market CAGR8.8%2027–2033
Target share15.7%from 9.3% today
Revenue ambition$1.26Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.3% | 15.7% | Behind |
| Revenue | $699M | $1.26B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 33.2% | 42.8% | Behind |
| Customer retention | 85.9% | 93.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Cell Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Source Tissue capability
A defensible second engine — invest in Source Tissue to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Cell Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Source Tissue
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $135M capacity & capability investment
- Greenlight bolt-on M&A in Source Tissue
- Authorise North America expansion plan
- Fund R&D program for Cell Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Human Primary Cells Market conversation — a $1.70B market you can size, segment and defend in minutes.
Market size · 2033$1.70Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,660+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Cell Type
Goal Grow share in Cell Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 3 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificLonza GroupMerck KGaA (MilliporeSigma)PromoCell GmbHATCC (American Type Culture Collection)BioIVTCell Applications Inc.Zen-Bio Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Human Primary Cells Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Human Primary Cells Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cardiac Medical Devices Market
Market size, share, segmentation and regional forecast.
$874M market · 2025 base year
View reportPap Tests and HPV Tests Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMedical Diagnostic Imaging Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportDental Prosthesis Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCord Blood Bank Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportArtificial Joint Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportIrtual Rehabilitation and Telerehabilitation Systems Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportIntelligent Glucose Meter Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportDermatology Lasers Market
Market size, share, segmentation and regional forecast.
$587M market · 2025 base year
View reportCAD-CAM Dental Systems Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportSagittal Suture Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMobile Dental Unit Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.